Alector Company Insiders
ALEC Stock | USD 1.59 0.08 4.79% |
Alector employs about 175 people. The company is managed by 18 executives with a total tenure of roughly 32 years, averaging almost 1.0 years of service per executive, having 9.72 employees per reported executive. Evaluation of Alector's management performance can provide insight into the firm performance.
Arnon Rosenthal CEO President CEO, Co-Founder, Director |
Tillman Gerngross Chairman Chairman of the Board, Co-Founder |
Alector Management Team Effectiveness
The company has return on total asset (ROA) of (0.1722) % which means that it has lost $0.1722 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9026) %, meaning that it created substantial loss on money invested by shareholders. Alector's management efficiency ratios could be used to measure how well Alector manages its routine affairs as well as how well it operates its assets and liabilities.Alector Workforce Comparison
Alector is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 795. Alector totals roughly 175 in number of employees claiming about 22% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (12.17) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $12.17. Alector Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alector insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alector's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alector insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arnon Rosenthal over two weeks ago Acquisition by Arnon Rosenthal of 45700 shares of Alector at 1.42 subject to Rule 16b-3 | ||
Yaffe Kristine over a month ago Disposition of 1000 shares by Yaffe Kristine of Alector at 1.44 subject to Rule 16b-3 | ||
Altmeyer Mark over a month ago Acquisition by Altmeyer Mark of 9450 shares of Alector at 1.63 subject to Rule 16b-3 | ||
Grasso Marc over a month ago Disposition of 16488 shares by Grasso Marc of Alector at 1.3384 subject to Rule 16b-3 | ||
Arnon Rosenthal over a month ago Disposition of 52087 shares by Arnon Rosenthal of Alector at 1.3384 subject to Rule 16b-3 | ||
Scheller Richard H over two months ago Acquisition by Scheller Richard H of 15833 shares of Alector subject to Rule 16b-3 | ||
Arnon Rosenthal over six months ago Disposition of 15186 shares by Arnon Rosenthal of Alector at 6.2181 subject to Rule 16b-3 | ||
Arnon Rosenthal over six months ago Acquisition by Arnon Rosenthal of 610500 shares of Alector subject to Rule 16b-3 |
Alector Notable Stakeholders
An Alector stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alector often face trade-offs trying to please all of them. Alector's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alector's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Arnon Rosenthal | President CEO, Co-Founder, Director | Profile | |
Tillman Gerngross | Chairman of the Board, Co-Founder | Profile | |
Sara KenkareMitra | President Development | Profile | |
Calvin Yu | Vice President - Finance | Profile | |
Saraswati KenkareMitra | President Development | Profile | |
Virginia MBA | Chief Strategy | Profile | |
Norah Conway | Program Portfolio | Profile | |
Gary MD | Chief Officer | Profile | |
Katie Hogan | Senior Relations | Profile | |
Marc MD | Chief Officer | Profile | |
Kristina MPH | Pharmacovigilance, Regulatory | Profile | |
Giacomo MD | Chief Officer | Profile | |
Michelle Corral | VP Relations | Profile | |
MS MBA | Interim Officer | Profile | |
Peter Heutink | Chief Officer | Profile | |
Danielle JD | General Counsel | Profile | |
Clare MBA | Chief Officer | Profile | |
Erica Jefferson | VP Affairs | Profile |
About Alector Management Performance
The success or failure of an entity such as Alector often depends on how effective the management is. Alector management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alector management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alector management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Alector operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 269 people.
Please note, the presentation of Alector's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alector's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alector's management manipulating its earnings.
Alector Workforce Analysis
Traditionally, organizations such as Alector use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alector within its industry.Alector Manpower Efficiency
Return on Alector Manpower
Revenue Per Employee | 574.6K | |
Revenue Per Executive | 5.6M | |
Net Loss Per Employee | 680.3K | |
Net Loss Per Executive | 6.6M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 16.7M |
Complementary Tools for Alector Stock analysis
When running Alector's price analysis, check to measure Alector's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alector is operating at the current time. Most of Alector's value examination focuses on studying past and present price action to predict the probability of Alector's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alector's price. Additionally, you may evaluate how the addition of Alector to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Fundamental Analysis View fundamental data based on most recent published financial statements |